NCT02871401 - A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 3, 2018

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

Valganciclovir

Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.

DRUG

Placebo

Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville